Endocyte and Oncothyreon Look to Benefit From Enhancements to U.S. Patent System

Five Star Equities Provides Stock Research on Endocyte and Oncothyreon

Marketwired

NEW YORK, NY--(Marketwire -05/15/12)- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of competing companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Endocyte, Inc. (ECYT) and Oncothyreon Inc. (ONTY).

Access to the full company reports can be found at:

www.FiveStarEquities.com/ECYT
www.FiveStarEquities.com/ONTY

The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a press release: "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Endocyte, a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, recently announced financial results for the first quarter ending March 31, 2012. The company reported a net loss for the first quarter of 2012 of $9.8 million, compared to $7.2 million for the same period in 2011.

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The company recently reported that net income for the quarter ended March 31, 2012 was $9.7 million, compared with a net loss of $7.1 million for the comparable period in 2011.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.

Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer

Contact:

Five Star Equities
Email Contact

View Comments (0)